Probiotic skin therapy improves eczema in children, NIH study suggests – tech2.org

Probiotic skin therapy improves eczema in children, NIH study suggests


News release

Wednesday, September 9, 2020

An experimental treatment for eczema that safely reduces the skin microbiome reduces disease severity and aims to increase the quality of life for children up to the age of 3, a National Institutes of Health Study found is. Researchers continue these improvements for eight months after treatment is discontinued Science Translational Medicine.

Atopic dermatitis, commonly called eczema, is a chronic inflammatory skin disease characterized by dry, itchy skin and rashes. The disease is most common in children and is associated with increased risk of asthma, hay fever and food allergies. While available treatments can help manage eczema symptoms, current options can be expensive, and many require multiple daily applications.

Experimental therapy has strains of vivacity Rosmonas mucosa-A bacterium is naturally present on the skin- is fundamentally different from healthy volunteers and develops in carefully controlled laboratory conditions. For four months, clinical trial participants or their carers periodically applied this probiotic therapy to areas of skin affected by eczema.

“A child suffering from eczema, which can be itchy, painful and distracting for the child, is also very difficult for the whole family,” said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), NIH. said. , Which led the study. “These early-stage findings suggest that R. Mucosa Therapy can help relieve some children of both the burden of eczema symptoms and the need for daily treatment. ”

Many genetic and environmental factors contribute to eczema, and scientists are learning more about the role that the skin microbiome plays in this condition. In 2016, NIAID researchers reported that R. Mucosa Results from improved cell culture and mouse models of eczema in strains isolated from healthy human skin.

To build on these preclinical findings, NIAID initiated a phase 1/2 clinical trial at the NIH Clinical Center in Bethesda, Maryland to assess for safety and potential benefits. R. Mucosa Medicine in people with eczema. Interim results for 10 adults and five children between 9 and 14 years of age in 2018 indicated that treatment was safe and associated with reduced eczema severity. Since then, the trial has enrolled an additional 15 children, ranging in age from 3 to 16, for a total of 20 children with mild to severe eczema.

Twice weekly for three months and every other day for an additional month, children or their carers sprayed a water solution containing sugar. R. Mucosa On areas of skin with eczema. For the first 15 children enrolled in the study, live supplements R. Mucosa It was gradually increased every month. The last five children to enroll received the same dose over a four-month treatment period. Regardless of the dosing strategy, no serious adverse events were attributed to therapy.

“Most children in the study experienced substantial improvement in their skin and overall well-being R. Mucosa Treatment. Encouragingly, medical bacteria persist on the skin and continue to provide benefits even after the therapy is discontinued, ”said Ian Miles, MD, head of testing, NIAID. “These results support a large study to assess the safety and effectiveness of this experimental treatment by comparison with placebo.”

Seventeen eczema of 20 children experienced more than 50% improvement in severity after treatment. Improvement occurred on all treated skin sites, including the inner elbow, inner knees, hands, trunk, and neck. Scientists also noticed that the skin’s barrier function increased – it has the ability to seal in moisture and keep out allergens. Additionally, most children require less corticosteroids to manage their eczema, experience less itching, and reported better quality of life after therapy. These benefits remain after treatment ends and therapy R. Mucosa Stretching remained on the skin for eight months.

NIAID researchers better understand how R. Mucosa Therapy improves eczema symptoms. They found that the treated skin had increased microbial diversity and reduced levels Staphylococcus aureus-A bacterium known to exacerbate eczema.

In addition to imbalances in the microbiome, people with eczema lack some lipids, or oils, in their skin. By conducting experiments in cell and animal models of eczema, NIAID scientists found that a specific set of lipids produced R. Mucosa Isolated strains from healthy skin can induce skin repair processes and promote the turnover of skin tissue. Study participants had increased levels of these lipids on their skin after treatment R. Mucosa.

Researchers emphasize that additional studies are needed to advance the mechanism R. Mucosa Therapy and to find out whether genetic or other factors may explain why some participants did not benefit from experimental treatment.

Initial evaluation of cutaneous treatment efficacy for more information on the full phase 1/2 study Roseomonas In atopic dermatitis (BACTE)RiAD), using the identifier NCT03018275, see ClinicalTrials.gov.

NIH is specifically licensed R. Mucosa Therapy Biosciences plans to pursue this potential treatment through further clinical development of the therapy, and the company plans to begin enrollment in a Phase 2 placebo-controlled trial later this month. For more information about this study, see ClinicalTrail, an assessment for mild to moderate atopic dermatitis in children, adolescents, and adults (2 years and older). Using the identifier N004504279.

NIAID supports and supports research at the NIH, across the United States, and worldwide – to study the causes of infectious and immune-mediated diseases, and to develop better tools to prevent, diagnose and treat these diseases for. News releases, fact sheets and other NIAID related material are available on the NIAID website.

About National Institutes of Health (NIH):The NIH, the nation’s medical research agency, comprises 27 institutes and centers and is a component of the US Department of Health and Human Services. The NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH… Turning Discovery into Health®

The reference

Ia myles and others. Therapeutic reactions to Rosmonas mucosa Atopic dermatitis may involve lipid-mediated TNF-associated epithelial repair. Science Translational Medicine DOI: 10.1126 / scitranslmed.aaz8631 (2020).

###

    .

Leave a Reply

Your email address will not be published.